News Releases

Trovagene to Present at Upcoming Healthcare Conferences
Stifel 2015 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum

SAN DIEGO, Nov. 16, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the Stifel 2015 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.

A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease.

Stifel 2015 Healthcare Conference

Trovagene is scheduled to present at the Stifel 2015 Healthcare Conference, taking place at The New York Palace Hotel, New York, on Tuesday, November 17, at 2:15 a.m. EST. The presentation will be webcast live at http://www.veracast.com/webcasts/stifel/healthcare2015/64109570736.cfm and can also be accessed through the investor relations page at www.trovagene.com.

Canaccord Genuity Medical Technologies and Diagnostics Forum

Trovagene is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum 2015 at the Westin Grand Central in New York, on Thursday, November 19, at 4:30 p.m. EST. The presentation will be webcast live at http://www.wsw.com/webcast/canaccord20 and can also be accessed through the investor relations page at www.trovagene.com.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.  The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Contacts






Investor Relations


Media Relations

David Moskowitz and Amy Caterina

Investor Relations


Ian Stone

Account Director

Trovagene, Inc.


Canale Communications, Inc.

858-952-7593


619-849-5388

ir@trovagene.com


ian@canalecomm.com

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

SOURCE Trovagene, Inc.